NDLI: GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.

Please wait, while we are loading the content...

Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis.

Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

Assessing medication burden and polypharmacy: finding the perfect measure.

Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.

Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications.

Apremilast for the management of moderate to severe plaque psoriasis.

GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.

Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.

Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).

Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.

GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Lamos, Elizabeth Mary Malek, Rana Davis, Stephen N.
Description	Country affiliation: United States Author Affiliation: Lamos EM ( a Division of Endocrinology , Diabetes and Metabolism, University of Maryland School of Medicine , Baltimore , MD , USA.); Malek R ( a Division of Endocrinology , Diabetes and Metabolism, University of Maryland School of Medicine , Baltimore , MD , USA.); Davis SN ( b Department of Medicine , University of Maryland Medical Center , Baltimore , MD , USA.)
Abstract	INTRODUCTION: Polycystic ovarian syndrome (PCOS) affects many women of child-bearing age and is characterized by hyperandrogenism, ovulatory and metabolic dysfunction. A primary treatment goal is weight reduction. The weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), previously demonstrated in diabetic and obese non-diabetic patients, offer a unique opportunity to expand the medical options available to PCOS patients. Areas covered: Available clinical trials of glucagon-like peptide-1 receptor agonist therapy in PCOS were reviewed. Literature was searched from PubMed using appropriate search terms up to November 2016. Expert commentary: The available studies of GLP-1 RA therapy in the treatment of excess body weight in women with PCOS demonstrate that exenatide and liraglutide are effective in weight reduction either as monotherapy or in combination with metformin. A few studies showed that androgens may be modestly decreased and menstrual frequency may be increased. Eating behavior may be improved with liraglutide therapy. Glucose parameters are generally improved. GLP-1RAs were well-tolerated, with nausea being the most significant adverse side effect. Barriers to utilization may be the short duration studies, lack of familiarity of the medication, the route of administration (injection) and the variable outcomes on ovulation and hyperandrogenism.
File Format	HTM / HTML
ISSN	17512433
Journal	Expert Review of Clinical Pharmacology
e-ISSN	17512441
Language	English
Publisher	Taylor & Francis
Publisher Date	2017-02-13
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology
Content Type	Text
Resource Type	Article
Subject	Pharmacology, Toxicology and Pharmaceutics Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.

A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.

Current trends in the treatment of polycystic ovary syndrome with desire for children

Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials

Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.

GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.

Similar Documents

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.

A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.

Current trends in the treatment of polycystic ovary syndrome with desire for children

Acupuncture for treating polycystic ovary syndrome: guidance for future randomized controlled trials

Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.

GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.